Monoclonal Anti-Influenza A virus NA (H1N1) (Victoria/2570/2019) Antibody, Human IgG1 (8E5) (MALS verified)

사용자 리뷰
제품 번호/규격
가격
수량
NEE-MY2069-100ug
$360.00
NEE-MY2069-1mg (500ug X 2)
$2380.00
ETA of in-stock products:2 business days
총 항목 수 제품 금액$ 0

제품 세부정보

  • Source

    Monoclonal Anti-Influenza A virus NA (H1N1) (Victoria/2570/2019) Antibody, Human IgG1 (8E5) is a chimeric monoclonal antibody recombinantly expressed in HEK293, which combines the variable region of a mouse monoclonal antibody with human constant domain.

  • Antibody Type

    Recombinant Monoclonal

  • Clone

    8E5

  • Isotype

    Human IgG1, Kappa

  • Host Species

    Mouse

  • Reactivity

    Influenza A virus (Victoria/2570/2019)

  • Immunogen

    Recombinant Influenza A [Victoria/2570/2019(H1N1)] Neuraminidase (NA) Protein is expressed from human 293 cells

  • Specificity

    Specifically recognizes Influenza A [Victoria/2570/2019(H1N1)] Neuraminidase (NA) Protein.

  • Cross Verification

    This product No cross-reactivity in ELISA with
    Influenza B [Austria/1359417/2021] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V5245).
    Influenza B [PHUKET/3073/2013] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V5246).
    Influenza A [Darwin/6/2021] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V5247).
    Influenza A [Sydney/5/2021] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V5248).
    Influenza A [A/Darwin/9/2021 (H3N2)] Neuraminidase (NA) Protein, His Tag (Cat. No. NE2-V5249).
    Influenza A [turkey/Germany-MV/R2472/2014(H5N8)] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V5249).
    Influenza A [A/Thailand/1(KAN-1)/2004(H5N1)] Neuraminidase (NA) Protein, His Tag (Cat. No. HA1-V5245).
    Influenza A [Guangdong/18SF020(H5N6)] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V524h).
    Influenza A [Wisconsin/588/2019(H1N1)] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V524k).
    Influenza A [Wisconsin/67/2022(H1N1)] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V524m).

  • Purification

    Protein A purified / Protein G purified.

  • Aggregation

    Less than 10%, as determined by SEC-MALS.

  • Concentration

    Please refer to the Certificate of Analysis (CoA).

  • Form

    Lyophilized

  • Formulation

    Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Reconstitution

    Please refer to the Certificate of Analysis (CoA) for specific instructions.

  • Shipping

    Lyophilized product is shipped at ambient temperature.

  • Storage

    For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

고객님도 확인한 상품

데이터 표시

  • Bioactivity-ELISA

     Neuraminidase (NA) ELISA

    Immobilized Influenza A [Victoria/2570/2019(H1N1)] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V524e) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Influenza A virus NA (H1N1) (Victoria/2570/2019) Antibody, Human IgG1 (8E5) (Cat. No. NEE-MY2069) with a linear range of 0.3-5 ng/mL (QC tested).

    Protocol

사용자 리뷰
댓글 남기기

배경 소개

Influenza, commonly known as 'the flu', is an infectious disease of birds and mammals caused by RNA viruses of the family Orthomyxoviridae, the influenza viruses. The virus is divided into three main types (Influenzavirus A, Influenzavirus B, and Influenzavirus C), which are distinguished by differences in two major internal proteins (hemagglutinin (HA) and neuraminidase (NA), which are the most important targets for the immune system. Hemagglutinin binds to the sialic acid-containing receptors on the surface of host cells during initial infection and at the end of an infectious cycle which makes it a great target for vaccine studies.

프론티어 진행

 
의약품 개발 진행
  • 영어 이름:

    Neuraminidase

  • 카테고리:

  • 상장 의약품 수:

    4 상세

  • 임상 의약품 수:

    10 상세

  • 최고 개발 단계:

    Approved

연락하기
신약 후보물질 라이선싱
더 많이 알아보기
  • 기본 제품 정보
  • 제품 세부정보
  • 고객님도 확인한 상품
  • 데이터 표시
  • 사용자 리뷰
  • 배경
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호